Navigation Links
The MaxCyte(R) STX(TM) Scalable Transfection System to be Presented at the Rapid Fire Innovation Session at LabAutomation2009
Date:1/26/2009

GAITHERSBURG, Md., Jan. 26 /PRNewswire/ -- MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces the presentation of the MaxCyte(R) STX(TM) Scalable Transfection System at LabAutomation2009 in the Rapid Fire Innovation Session, a joint program of the Association for Laboratory Automation (ALA) and the Laboratory Robotics Interest Group (LRIG). The Rapid Fire Innovation Session showcases the latest innovations in laboratory automation and technology products and services. The presentation will take place Monday evening, January 26, at 7:00PM, at LabAutomation2009 in Palm Springs, CA.

"The Rapid-Fire Innovation Session at LabAutomation2009 provides an opportunity for scientists and engineers to learn about innovative technologies that can enhance and improve the capabilities and productivity of R&D labs," says Dr. Karen Donato, Vice President of Sales and Marketing, who will be presenting the MaxCyte STX technology in the session. "The selection of the MaxCyte STX for this session attests to the uniqueness of MaxCyte's large scale transfection technology. Using the MaxCyte STX, more than ten billion cells can be transfected in less than 30 minutes with one or more loading agents at efficiencies and cell viabilities often exceeding 90%. The speed, scale, and flexibility of our technology allow the development of an expanded range of relevant cell-based assays for drug discovery. We are pleased to have the opportunity to present and demonstrate the MaxCyte STX technology at LabAutomation2009."

"The MaxCyte STX is being viewed by the pharmaceutical industry as an innovative and enabling technology for cell modification for both research and large scale cell-based applications in drug discovery," says MaxCyte President and CEO, Doug Doerfler. "The MaxCyte STX can produce billions of high quality transfected cells in minutes compared to time consuming and inconsistent alternative methods. With the infinite number of combinations of cell types and loading agents that can be processed reproducibly with the MaxCyte STX, drug discovery scientists now have a powerful tool for modifying cells in ways that will improve the design, development, and conduct of screening assays, increasing the likelihood of finding successful drug candidates."

MaxCyte will also be participating in LabAutomation2009 as an exhibitor and offering demonstrations of the MaxCyte STX during the conference.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed the MaxCyte(R) STX(TM) Scalable Transfection System expressly for rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cellbased applications.

For more information, http://www.maxcyte.com/cell-based-screening.shtml.


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
2. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
3. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
4. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
5. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
6. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
9. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):